Revelation Biosciences, Inc. (REVB)
Develops drugs that reset the immune system to treat kidney disease and inflammation.
$1.04-0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-89.4%
The outlook
REVB is trading near the bottom of its 52-week range, well below both its 50- and 200-day moving averages. Analyst coverage shows a notably bullish average price target sitting roughly 18x above the current price, though overall sentiment leans bearish. The stock remains highly volatile and deeply depressed from recent highs.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +1755% vs current price
Analyst price target
~12-month · 2 analysts$19.25average target+1754.7% vs now
Now $1.04
Low $16.00High $22.50
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$4.1M
52-wk high
$11.72
52-wk low
$0.88
50-day avg
$1.05
200-day avg
$2.27
Trailing P/E
—